Compile Data Set for Download or QSAR
Report error Found 360 Enz. Inhib. hit(s) with all data for entry = 1963
TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348314BDBM348314(US9790229, Compound 37 | US10577374, Compound 37)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348559BDBM348559(US9790229, Compound 282 | US10577374, Compound 282)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348431BDBM348431(US9790229, Compound 154 | US10577374, Compound 154)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348560BDBM348560(US9790229, Compound 283 | US10577374, Compound 283)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348432BDBM348432(US9790229, Compound 155 | US10577374, Compound 155)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348557BDBM348557(US9790229, Compound 280 | US10577374, Compound 280)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348429BDBM348429(US9790229, Compound 152 | US10577374, Compound 152)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348558BDBM348558(US9790229, Compound 281 | US10577374, Compound 281)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348430BDBM348430(US9790229, Compound 153 | US10577374, Compound 153)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348433BDBM348433(US9790229, Compound 156 | US10577374, Compound 156)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348562BDBM348562(US9790229, Compound 285 | US10577374, Compound 285)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348434BDBM348434(US9790229, Compound 157 | US10577374, Compound 157)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348583BDBM348583(US9790229, Compound 306 | US10577374, Compound 306)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348327BDBM348327(US9790229, Compound 50 | US10577374, Compound 50)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348584BDBM348584(US9790229, Compound 307 | US10577374, Compound 307)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348582BDBM348582(US9790229, Compound 305 | US10577374, Compound 305)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348326BDBM348326(US9790229, Compound 49)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348587BDBM348587(US9790229, Compound 310 | US10577374, Compound 310)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348588BDBM348588(US9790229, Compound 311 | US10577374, Compound 311)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348585BDBM348585(US9790229, Compound 308 | US10577374, Compound 308)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348329BDBM348329(US9790229, Compound 52 | US10577374, Compound 52)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348586BDBM348586(US9790229, Compound 309 | US10577374, Compound 309)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348579BDBM348579(US9790229, Compound 302 | US10577374, Compound 302)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348323BDBM348323(US9790229, Compound 46 | US10577374, Compound 46)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348577BDBM348577(US9790229, Compound 300 | US10577374, Compound 300)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348578BDBM348578(US9790229, Compound 301 | US10577374, Compound 301)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348599BDBM348599(US9790229, Compound 322 | US10577374, Compound 322)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348600BDBM348600(US9790229, Compound 323 | US10577374, Compound 323)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348597BDBM348597(US9790229, Compound 320 | US10577374, Compound 320)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348603BDBM348603(US9790229, Compound 326 | US10577374, Compound 326)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348604BDBM348604(US9790229, Compound 327 | US10577374, Compound 327)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348601BDBM348601(US9790229, Compound 324 | US10577374, Compound 324)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348591BDBM348591(US9790229, Compound 314 | US10577374, Compound 314)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348592BDBM348592(US9790229, Compound 315 | US10577374, Compound 315)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348589BDBM348589(US9790229, Compound 312 | US10577374, Compound 312)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348590BDBM348590(US9790229, Compound 313 | US10577374, Compound 313)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348595BDBM348595(US9790229, Compound 318 | US10577374, Compound 318)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348596BDBM348596(US9790229, Compound 319 | US10577374, Compound 319)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348593BDBM348593(US9790229, Compound 316 | US10577374, Compound 316)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348594BDBM348594(US9790229, Compound 317 | US10577374, Compound 317)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348616BDBM348616(US9790229, Compound 339 | US10577374, Compound 339)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348614BDBM348614(US9790229, Compound 337 | US10577374, Compound 337)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348618BDBM348618(US9790229, Compound 341 | US10577374, Compound 341)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348606BDBM348606(US9790229, Compound 329 | US10577374, Compound 329)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348611BDBM348611(US9790229, Compound 334 | US10577374, Compound 334)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348612BDBM348612(US9790229, Compound 335 | US10577374, Compound 335)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348609BDBM348609(US9790229, Compound 332 | US10577374, Compound 332)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348632BDBM348632(US9790229, Compound 355 | US10577374, Compound 355)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348629BDBM348629(US9790229, Compound 352 | US10577374, Compound 352)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Sunesis Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 348630BDBM348630(US9790229, Compound 353 | US10577374, Compound 353)
Affinity DataIC50: 100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

Displayed 1 to 50 (of 360 total ) | Next | Last >>
Jump to: